Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 for moderately to severely active ulcerative colitis
jRCT2031240228Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoint: Percentage of participants achieving clinical remission at Week 12 based on modified Mayo score. Started Mar 2024; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031240228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240228.